Latest Obroncology Podcast Episodes
To Get Better Cancer Drugs Faster, Is It Time for an “International FDA"?
Peer-Spectives - June 26, 2024 18:40 - 13 minutesFrom ASCO 2024 The time it takes for a novel cancer therapy to go from investigational new drug application to U.S. Food and Drug Administration (FDA) approval is typically longer than a decade. “There has to be a better way,” says Bob T. Li, MD, PhD, MPH, a medical oncologist at Memorial Sloa...
"Very Important" Myeloma Data: ASCO Highlights, Smoldering Challenges, and More
Peer-Spectives - June 20, 2024 15:23 - 12 minutesFrom ASCO 2024, Dr. Robert Figlin speaks with Dr. Samer Al Hadadi from University of Arkansas. "Very Important" Myeloma Data: ASCO Highlights, Smoldering Challenges, and More.
Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected"
Peer-Spectives - June 17, 2024 15:18 - 10 minutesFrom ASCO 2024, Dr. Robert Figlin talks with Dr. Lauren Averett Byers from MD Anderson Cancer Center. Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected"
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says
Peer-Spectives - June 13, 2024 15:15 - 25 minutesFrom ASCO 2024 New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says. Dr. Robert Figlin speaks with Dr. Christian Blank from Leiden University
Should All Breast Cancer Patients Get T-DXd? "Results of DESTINY-Breast06 Do Suggest That"
Peer-Spectives - June 10, 2024 15:05 - 10 minutesFrom ASCO 2024, Dr. Robert Figlin welcomes Dr. Aditya Bardia from UCLA Health Jonsson Comprehensive Cancer Center. Should All Breast Cancer Patients Get T-DXd? "Results of DESTINY-Breast06 Do Suggest That"
Oncologist Shortage “Has Gotten to the Crisis Level”
Peer-Spectives - May 06, 2024 20:04 - 10 minutesEspecially in rural areas, the growing oncologist shortage has “gotten to crisis level,” says Harsha Vyas, MD, president and founding partner of Cancer Center of Middle Georgia in Dublin. “We just don’t have enough supply of medical oncologists/hematologists,” he tells Robert A. Figlin, MD, the ...
“Monster Improvements” in CLL Care Prompt Questions About BTK Inhibitor Use
Peer-Spectives - April 16, 2024 16:44 - 9 minutesThe development of noncovalent Bruton tyrosine kinase (BTK) inhibitors and other advances in chronic lymphocytic leukemia treatment signify that the “future is really exciting,” says Jennifer A. Woyach, MD, professor in the Division of Hematology at The Ohio State University in Columbus. Dr. Woy...
“Better to Have Choices”: How New Data Transform EGFR-Mutated NSCLC Care
Peer-Spectives - March 29, 2024 18:57 - 10 minutesGiven recent data, how should oncologists choose a tyrosine kinase inhibitor (TKI) in patients with EGFR-mutated non-small cell lung cancer (NSCLC), and when should chemotherapy be introduced? “It’s better to have choices than not,” explains Paul Bunn, MD, the Dudley Chair in Cancer Research at ...
Practice-Changing Data Introduce “Whole New Challenge” in Prostate Cancer
Peer-Spectives - March 26, 2024 21:37 - 11 minutesThe treatment of biochemical recurrence in prostate cancer “is set for rapid development over the next few years,” says Edwin M. Posadas, MD, medical director of the Center for Uro-Oncology Research Excellence at the Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center. Data ...
FDA Approval for TIL Therapy “Real Milestone” That Has Been “Long Time Coming”
Peer-Spectives - March 21, 2024 17:02 - 11 minutesThe U.S. Food and Drug Administration’s recent accelerated approval of a tumor-infiltrating lymphocyte therapy in metastatic melanoma “is a real milestone,” after the approach was “pending for decades,” explains Jeffrey S. Weber, MD, PhD, deputy director at the NYU Langone Perlmutter Cancer Cen...
From “Fairytale” to Reality? Paradigm Shift in Bladder Cancer Care
Peer-Spectives - March 08, 2024 17:32 - 10 minutesRecent advances in metastatic urothelial carcinoma have meant that optimistic outcomes are “not as much of a fairytale,” says Robert Dreicer, MD, deputy director of the UVA Cancer Center and professor of medicine and urology at the University of Virginia School of Medicine in Charlottesville. Fr...
FDA Approvals, Pivotal Trial Data Change Approach to Breast Cancer Progression
Peer-Spectives - February 14, 2024 17:40 - 11 minutesRecent approvals by the U.S. Food and Drug Administration (FDA) and findings from pivotal clinical trials have changed care for patients with breast cancer that has progressed after frontline hormone therapy. Ruth M. O’Regan, MD, chair of medicine and Charles H. Dewey Professor at the University...
Controversies, Difficult Questions Arise in NSCLC Amid New Data
Peer-Spectives - February 14, 2024 17:39 - 10 minutesRecent data on the use of immunotherapy and targeted treatments in patients with advanced non-small cell lung cancer (NSCLC) have introduced a myriad of questions. These include controversial topics and difficult decisions, like when to incorporate CTLA-4 inhibition and what patients can expect ...
What FDA Approval of Belzutifan Means for Kidney Cancer Care
Peer-Spectives - February 05, 2024 21:15 - 10 minutesBelzutifan was recently approved by the U.S. Food and Drug Administration (FDA) for use in previously treated adults with advanced renal cell carcinoma. How should this drug best be incorporated into practice? Eric Jonasch, MD, professor in the Department of Genitourinary Medical Oncology at th...
Despite Lack of Head-to-Head Trials, Practice Patterns Shifting in Breast Cancer
Peer-Spectives - February 01, 2024 22:55 - 12 minutesCDK4/6 inhibitors “have really been a game changer” in metastatic breast cancer, according to Komal Jhaveri, MD, clinical director for early drug development and section head for endocrine therapy research at Memorial Sloan Kettering in New York City. However, optimal treatment strategies have b...
Which FDA Approvals, Other Advances Changed ER-Positive Breast Cancer Care in 2023?
Peer-Spectives - December 18, 2023 18:25 - 10 minutesFrom compelling data presented at the San Antonio Breast Cancer Symposium to the recent U.S. Food and Drug Administration approval of capivasertib, 2023 saw numerous key advances in breast cancer care. Aditya Bardia, MD, MPH, director of the breast cancer research program at Massachusetts Gen...
“New Disruptor” in Prostate Cancer: PSMA PET and Other Treatment Advances
Peer-Spectives - December 15, 2023 17:11 - 11 minutesFrom the use of prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) to advancements in targeted treatments, prostate cancer care is quickly evolving. Edwin M. Posadas, MD, director of the Experimental Therapeutics Program and director of the Center for Urologic Oncology ...
Practice-Changing Results in Prostate Cancer, as Enzalutamide Regimens Show Strong Benefit
Peer-Spectives - December 14, 2023 17:10 - 11 minutesResults of the recent EMBARK study show that both enzalutamide plus leuprolide and enzalutamide monotherapy significantly improved metastasis-free survival compared with leuprolide alone in patients with prostate cancer who have high-risk biochemical recurrence. Lead author Stephen Freedland, MD...
ER-Positive Breast Cancer Advances and Other Eagerly Anticipated Data at SABCS 2023
Peer-Spectives - November 20, 2023 18:37 - 11 minutesStudies involving high-risk, early-stage ER-positive breast cancer are among the most eagerly anticipated at this year’s San Antonio Breast Cancer Symposium (SABCS), to be held Dec. 5-9. Virginia Kaklamani, MD, professor of medicine in the division of hematology and medical oncology at the Univ...
Inside ODAC’s Vote on Sotorasib in Advanced and Metastatic NSCLC: Lessons Learned
Peer-Spectives - November 15, 2023 17:39 - 13 minutesLast month, a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) determined that progression-free survival (PFS) could not be reliably interpreted in a confirmatory clinical trial for sotorasib (Lumakras) used to treat KRAS G12C–mutated locally advanced or metastat...
First-Line Osimertinib Plus Chemo in NSCLC: How to Weigh Toxicity vs. Efficacy
Peer-Spectives - November 07, 2023 15:58 - 9 minutesHow should results of the FLAURA2 clinical trial be applied in practice? The study examined the use of osimertinib plus chemotherapy in the first-line treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared with osimertinib alone and found that progression-free survival wa...
What Recent “Outstanding Results” in MCL Mean for Practice
Peer-Spectives - October 27, 2023 20:31 - 11 minutes“Therapies are improving dramatically” in mantle cell lymphoma (MCL), according to Michael Wang, MD, professor in the department of lymphoma/myeloma, division of cancer medicine at the University of Texas MD Anderson Cancer Center in Houston. Dr. Wang presented updates on major advances in M...
The Quest to Cure CLL: “Remarkable” Results With New Strategy
Peer-Spectives - September 06, 2023 20:45 - 16 minutesRecent advances have provided new options for when and how best to treat patients with chronic lymphocytic leukemia (CLL). Trials of combination strategies have shown promise in providing patients the potential for unmaintained remissions. Marco Ruella, MD, an assistant professor of medicine in ...
Which Data From the 2023 World Conference on Lung Cancer Are Most Likely to Change Practice?
Peer-Spectives - August 15, 2023 15:41 - 14 minutesThe World Conference on Lung Cancer (World Lung) will be held in Singapore, September 9–12. The current president of International Association for the Study of Lung Cancer (IASLC), Heather A. Wakelee, MD, division chief of medical oncology at the Stanford Cancer Institute in California, shares w...
“Really Impactful” New Guidelines for Stage IV NSCLC With Driver Alterations
Peer-Spectives - August 03, 2023 15:15 - 15 minutesUpdates to the American Society for Clinical Oncology’s (ASCO’s) living guidelines for therapy in patients with stage IV non-small cell lung cancer (NSCLC) with driver alterations were recently released. Dwight H. Owen, MD, MS, from The Ohio State University Comprehensive Cancer Center – James, ...
More “Cage Rattling,” Less Talking: Susan Love’s Lessons for Oncologists
Peer-Spectives - July 18, 2023 14:55 - 13 minutesIn early July, beloved surgeon and breast cancer advocate Susan Love, MD, MBA, died at age 75 years, after a recurrence of leukemia. Dr. Love’s legacy extends beyond the lives of her patients and into the approaches and attitudes of her fellow physicians. Stephanie Graff, MD, medical advisor to ...
Will HER3 Targeting Change Breast Cancer Care?
Peer-Spectives - June 27, 2023 15:29 - 12 minutesHER2 inhibitors dramatically changed care for many breast cancers; however, less is known about HER3, which acts in concert with HER2. Does HER3 have the same potential to reshape treatment strategies? Erika Hamilton, MD, director of breast cancer and gynecologic cancer research at Sarah Cannon ...
“Practice-Expanding” Data on Adjuvant Osimertinib in NSCLC: Steps to Take Now
Peer-Spectives - June 26, 2023 23:02 - 13 minutesAlthough findings have suggested that adjuvant osimertinib is beneficial in early-stage non-smallcell lung cancer (NSCLC), some concerns have persisted. Balazs Halmos, MD, MS, associate director of clinical science, and director of both thoracic oncology and clinical cancer genomics at Montefio...
“Don't Just Throw Drugs Together”: How to Best Approach ESR1 Mutations in Breast Cancer
Peer-Spectives - June 20, 2023 12:00 - 13 minutesHow should community oncologists best approach ESR1 mutations in breast cancer, given the latest findings? Recent data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and elsewhere have shed light on issues related to ESR1 testing and treatment selection. Bob Fi...
mRNA Cancer Vaccines: When to Expect FDA Approval, and What’s Next?
Peer-Spectives - May 17, 2023 16:56 - 11 minutesRecent results demonstrated that mRNA vaccination improved recurrence-free survival among patients with melanoma. This has led to questions about what’s next for this promising intervention. Bob Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars Sinai Cancer in Los A...
Related Obroncology Topics